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Blood pressure self-monitoring in
pregnancy: examining feasibility in a
prospective cohort study
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Elizabeth Ewers3, Margaret Glogowska1, Sheila M. Greenfield2, Lucy Ingram3, Lisa Hinton1, Khalid S. Khan4,
Louise Locock5, Lucy Mackillop6, Christine McCourt7, Alexander M. Pirie3, Richard Stevens1
and Richard J. McManus1*
Abstract
Background: Raised blood pressure (BP) affects approximately 10% of pregnancies worldwide, and a high proportion
of affected women develop pre-eclampsia. This study aimed to evaluate the feasibility of self-monitoring of BP in
pregnancy in women at higher risk of pre-eclampsia.
Methods: This prospective cohort study of self-monitoring BP in pregnancy was carried out in two hospital trusts in
Birmingham and Oxford and thirteen primary care practices in Oxfordshire. Eligible women were those defined by the
UK National Institute for Health and Care Excellence (NICE) guidelines as at higher risk of pre-eclampsia. A total of 201
participants were recruited between 12 and 16 weeks of pregnancy and were asked to take two BP readings twice
daily three times a week through their pregnancy. Primary outcomes were recruitment, retention and persistence of
self-monitoring. Study recruitment and retention were analysed with descriptive statistics. Survival analysis was used to
evaluate the persistence of self-monitoring and the performance of self-monitoring in the early detection of gestational
hypertension, compared to clinic BP monitoring. Secondary outcomes were the mean clinic and self-monitored BP
readings and the performance of self-monitoring in the detection of gestational hypertension and pre-eclampsia
compared to clinic BP.
Results: Of 201 women recruited, 161 (80%) remained in the study at 36 weeks or to the end of their pregnancy, 162
(81%) provided any home readings suitable for analysis, 148 (74%) continued to self-monitor at 20 weeks and 107
(66%) at 36 weeks. Self-monitored readings were similar in value to contemporaneous matched clinic readings for both
systolic and diastolic BP. Of the 23 who developed gestational hypertension or pre-eclampsia and self-monitored, 9
(39%) had a raised home BP prior to a raised clinic BP.
Conclusions: Self-monitoring of BP in pregnancy is feasible and has potential to be useful in the early detection of
gestational hypertensive disorders but maintaining self-monitoring throughout pregnancy requires support and
probably enhanced training.
Keywords: Hypertension, Self-monitoring, Pregnancy, Pre-eclampsia
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Background
Hypertension in pregnancy, (defined as blood pressure
(BP) ≥140/90 mmHg), and pre-eclampsia (where there is
proteinuria ≥300 mg/24 h additonally after 20 weeks,
gestation) results in substantial maternal morbidity and
mortality worldwide [1, 2]. Furthermore, hypertension
during pregnancy has been linked to the development of
chronic hypertension and an increase in lifetime cardio-
vascular risk [3]. Raised BP in pregnancy also carries a
risk for the baby: pre-eclampsia is associated with fetal
growth restriction, low birth weight, preterm delivery,
respiratory distress syndrome, and admission to neonatal
intensive care [4–6].
Pre-eclampsia causes widespread vascular endothelial
dysfunction in the mother that can cause significant
increases in BP [7, 8]. Raised BP in the absence of pro-
teinuria is a risk factor for pre-eclampsia. Most cases of
pre-eclampsia are asymptomatic in the early stages. Early
hypertensive treatment and timely delivery can prevent
morbidity and potentially mortality, hence improving
detection is important [9].
Inadequate management of raised blood pressure, in
particular systolic hypertension, was a key finding
requiring action in the 2005–2008 UK Confidential
Enquiry into Maternal Deaths [10]. While the maternal
death rate from pre-eclampsia and eclampsia has since
fallen in the UK, it remains a leading cause of preventable
maternal death [9]. The current UK National Institute
for Health and Care Excellence (NICE) guideline rec-
ommends BP monitoring at routine antenatal visits
with increased frequency for those at higher risk of pre-
eclampsia, but without defining the testing interval
[11]. A large number of women develop pre-eclampsia
between antenatal visits, [12] with potentially serious
consequences [13]. BP self-monitoring could improve
detection of hypertensive disorders [14–16]. However,
there is no consensus regarding monitoring protocols
or home diagnostic thresholds.
The Blood Pressure Self-Monitoring in Pregnancy
(BuMP) study was a prospective cohort study which
aimed to evaluate the feasibility and acceptability of a
patient controlled intervention to detect hypertension
in pregnancy through self-monitoring, in higher risk
women. A qualitative study of women’s experiences of
self-monitoring will be reported separately.
Methods
A protocol was developed and registered for a feasibility
study of self-monitoring of BP in pregnancy utilising
experience from previous trials of self-monitoring in
hypertension [17–19]. (National Institute for Health
Research (NIHR) Central Research Network (CRN)
Portfolio number: 14,151).
Study participants
Eligible pregnant women were those able and willing to
self-monitor BP and defined by the NICE as at higher
risk of pre-eclampsia on the basis of any of the following
risk factors; aged 40 years or older; nulliparity (first preg-
nancy); pregnancy interval of more than 10 years; family
history of pre-eclampsia; previous history of pre-eclampsia;
history of hypertension in pregnancy, body mass index of
30 kg/m2 or above at booking; pre-existing vascular disease
such as hypertension; pre-existing renal disease; or multiple
pregnancy [11]. Potentially eligible women were identified
and provided with information about the study at routine
antenatal appointments. Recruitment took place in two
hospital trusts (in Oxford and Birmingham) and 13 primary
care practices across Oxfordshire by midwives, general
practitioners and medical staff.
Potential participants attended a study appointment
between 12 and 16 weeks of pregnancy, in addition to
their usual antenatal appointment, at which informed
consent was gained, baseline history and measurements
taken, a questionnaire completed regarding lifestyle and
demographics and training regarding self-monitoring
was delivered. Follow-up occurred at the time of routine
antenatal appointments at 16, 28 and 36 weeks of preg-
nancy. Women requiring admission to hospital or add-
itional clinic BP monitoring were asked to continue to
self-monitor if they felt able. A participant flowchart is
given in Additional file 1: Figure S1.
Blood pressure self-monitoring
Participants self-monitored BP using an automated elec-
tronic sphygmomanometer validated for use in pregnancy
and pre-eclampsia (Microlife WatchBP home) and were
asked to self-monitor taking two measurements both
morning and evening, following 5 min at rest, three
days a week (Monday, Wednesday and Friday) [15, 20].
Participants were provided with a simple colour coded
guideline including recommendations to contact rele-
vant health professionals in the case of high or low BP
readings (Additional file 2: Figure S2). Little is known
about self-monitored BP thresholds in pregnancy. Whilst
self-monitoring to monitor essential hypertension typically
uses lower thresholds at home compared to clinic, data
from population studies suggests that out-of-office meas-
urement is much closer to clinic BP levels in the absence
of selection on the basis of raised clinic BP (typical in
hypertensive populations) [21, 22]. Furthermore, setting
lower home thresholds in this observational study might
have led to inappropriate contact with maternity services
and anxiety. Therefore, in the guideline given to the
women, BP thresholds were set at the same level as clinic
thresholds.
Self-monitored BP readings were automatically recorded
by the monitors, additionally participating women were
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asked to note readings in a diary and could optionally text
their results via ‘Florence,’ an NHS telemonitoring service
(http://www.getflorence.co.uk/) which provided feedback
if any action was required. Health care professionals were
not blinded to the self-monitored readings.
For analysis, the BP readings downloaded from the
monitor were used in preference to diary readings. Mini-
mum criteria for mean self-monitored BP were defined
using standard criteria as: at least 12 readings over at
least 4 days, plausible levels (systolic BP 70-250 mmHg
and diastolic BP 40–150 mmHg), and without an implaus-
ible drop between readings (>50% decrease in successive
readings) (Additional file 3: Figure S3) [23]. Clinic read-
ings taken as part of usual care were recorded directly
from the maternity notes.
Outcome measures
The primary outcomes were numbers recruited and
retained, and persistence of self-monitoring. Retention
was defined as the proportion of women recruited who
remained in the study until miscarriage or delivery or
final follow-up at 36 weeks, whichever was longer. Persist-
ence was defined as the proportion of women who self-
monitored until miscarriage or delivery or final follow-up
at 36 weeks, whichever was longer.
Secondary outcomes, included the difference between
mean self-monitored and clinic BP (systolic and diastolic);
and the performance of self-monitored BP in the detection
of gestational hypertension compared to the reference of
clinic BP.
Final diagnostic verdicts were provided by an obstetric
medicine consultant (LM) or an obstetrician (AP), who
reviewed the antenatal notes from usual care. These diag-
noses were independently reviewed by RM and where more
than one diagnosis was recorded, the final diagnosis for that
pregnancy was taken (for example gestational hypertension
that developed subsequently into pre-eclampsia was defined
as the latter). Birthweight centiles of the babies born in the
study were calculated using the customised weight centiles
GROW (Gestation Related Optimal Weight) [24].
Sample size calculation
Feasibility studies do not require a formal sample size
calculation but a sample of 200 women was considered
sufficient to both allow experience with self-monitoring
and to include women who developed pregnancy induced
hypertension subsequently [25].
Statistical analysis
Persistence
A Kaplan-Meier (KM) survival curve was plotted to de-
scribe the persistence of self-monitoring, based on the
dates of participants’ final home readings. The plot was
constructed on participants from 20 weeks gestation
onwards to allow for the fact that women started moni-
toring at different times between 10 and 18 weeks.
Women were censored at delivery or dropout.
Mean differences
Self-monitored and clinic BP readings were plotted be-
tween weeks 12 and 38 weeks for participants who had
both self-monitored and clinic BP data in the same week
of pregnancy. Data on clinic BP readings were extracted
from the participants’ standard antenatal records. Home
BP readings were averaged across the same week as a
particular clinic reading.
Time to first raised reading
Further KM survival curves were produced from 12 to
40 weeks to present the time to the first raised BP, separ-
ately for home and clinic BP readings in women who
had both types of readings. Rather than using average
BP for home and clinic, this analysis used raised BP
readings on a single occasion. A raised clinic BP was de-
fined as a reading recorded in the clinical record ≥140/
90 mmHg. The self-monitoring instructions advised
women to measure their own BP at least twice per ses-
sion and to act on the second reading. The first reading
was therefore dropped from the base case analysis. Be-
cause home readings were repeated if raised, a raised
home reading was defined as the final reading of any
monitoring “session” ≥140/90 mmHg. Session length
was defined as 15 min for high readings (defined as
≥150/100 mmHg) and 5 h for raised readings (140–149/
90-99 mmHg), in order to capture data collected in ac-
cordance with the participants’ instructions. [Additional
file 2: Figure S2]. The survival curves were compared
using a log-rank test.
Diagnostic accuracy statistics
Women were classed as having hypertension based on
home readings if they had at least one episode of raised
home BP (Additional file 4: Table S1). Another classifica-
tion was based on clinic BP readings (Additional file 4:
Table S1). These classifications were compared with the
final clinical diagnosis of hypertension, the gold stand-
ard. Sensitivity, specificity, positive and negative predict-
ive values were produced for both home and clinic BP
monitoring.
Sensitivity analyses
For time to first raised reading, considered the alterna-
tive strategies of including the first home reading of each
session, and using a lower threshold for raised home
readings of 135/85 mmHg (retaining 140/90 mmHg for
clinic).
All analyses were carried out using STATA 12SE
(StataCorp, LP).
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Ethical approval
A favourable ethical review for this study was obtained
from South Central – Oxford Research Ethics Commit-
tee B (reference; 12 SC 0625, 12/12/2012).
Results
Participant recruitment
Two hundred one participants were recruited between
April 2013 and January 2014, mostly through secondary
care (n = 162, 81%) with a further 39 (19%) recruited via
13 general practice sites. Women were recruited at
between 10 and 18 weeks of pregnancy and followed
thereafter. At baseline, they had a mean age of 31.4 (SD
5.5), a BMI of 28.1 (SD 6.6), and a mean clinic BP of
117 ± 10/71 ± 9 mmHg (Table 1). Few women had self-
monitored BP previously (4.8%). Participants showed
similar levels of anxiety to normative data from working
adult women in the age range (STAI: 33.7 [BuMP] vs
35.0 [working adult women aged 24–35]) [26]. Half
(50%) reported having professional qualifications or a
degree (vs 43% of women aged 25–34 with a degree level
qualification or above nationally) [27].
Babies born in the study had a mean GROW birthweight
centile of 45.7 (SD 29.2, n = 166).
Retention in the study and persistence with self-monitoring
Of the 201 women who entered the study, 168 (84%)
continued until final follow-up at 36 weeks (or delivery/
miscarriage if earlier) of whom 161 (80%) were in the
study at 36/40 gestation (Fig. 1). The average gestation
at delivery was 38.2 weeks (SD 2.2).
One hundred sixty-two (81%) women provided any
suitable self-monitored BP data for the analysis, a total
of 16,940 home readings (Fig. S3) [23]. Of these 162
women, 139 (86%) continued to self-monitor up to
28 weeks or delivery/miscarriage, if sooner, and 107
(66%) continued to 36 weeks or delivery if sooner. Per-
sistence with self-monitoring is shown in Fig. 2.
Self-monitored and clinic blood pressure readings
Self-monitored and clinic BP measurements from week 12
to week 38 of pregnancy are shown in Fig. 3. Most systolic
and all diastolic point estimates for home and clinic read-
ings were within 5 mmHg and the 95% confidence inter-
vals overlapped for both systolic and diastolic BP other
than systolic BP at 20 weeks. However, although this work
was not powered to detect such differences, the point esti-
mates for systolic clinic BP tended to be higher than home
readings whereas diastolic were if anything reversed.
Detection of raised blood pressure in women with
confirmed gestational hypertension and pre-eclampsia
Final diagnostic verdicts were completed on 157/201
women, including two women who withdrew with
permission for notes review (eight sets of notes could
not be located or were incomplete and 36 participants
withdrew without providing permission for notes review).
Overall 28/157 (18%) women developed pregnancy in-
duced hypertension. This can be broken down as follows:
considering women developing new hypertension follow-
ing 20 weeks of pregnancy, 20 (13%) developed gestational
hypertension, of whom 5 (3%) went on to develop pre-
Table 1 Baseline characteristics
Number of
participants
Mean(SD)
or %
Demographics
Age (years) 201 31 (6)
BMId 198 28 (7)
Ethnicity
White 157 78
Mixed 8 4
Asian or Asian British 18 9
Black or Black British 8 4
Chinese or other 6 3
Unknown/not disclosed 4 2
Eligibilitya
Age≥ 40 18 9
BMI ≥30 61 31
Multiple pregnancy 35 17
First pregnancy 87 43
Diagnosed with high BP pre-pregnancy 18 9
High BP in previous pregnancy 42 21
Pre-eclampsia in previous pregnancy 24 12
Family history of pre-eclampsia 39 20
Pregnancy interval > 10 yrs 6 3
Renal disease 6 3
Clinic BP at baselineb,d
Systolic 200 118 (10)
Diastolic 200 71 (9)
Education (highest)
Professional qualifications or degree 101 50
School qualifications only 74 37
No formal qualifications 7 4
Unknown 19 9
Other baseline characteristics
Converted STAI scorec 179 34 (11)
Measured BP at home previously 9 25
aParticipants required one or more eligibility criteria
bClinic BP at baseline included readings up to 18 weeks pregnancy
cSix-item version of the State-Trait Anxiety Inventory (STAI-6) was converted
pro-rata to range 20–80.
dThere was missing baseline information from one participant and 2 further
participants did not wish to provide BMI data
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Lost to follow-up before 28 weeks 
gestation (n= 28, 14%)
- Lack of time n= 5
- Family illness n=3
- Moved house n=4
- Unknown n=16
Pregnancy loss and premature birth
(n=6, 3%)
- Miscarriage n=4
- Premature delivery n=1
- Stillbirth n=1
Recruited (n= 201)
Lost to follow-up between 28 weeks 
and 36 weeks gestation (n= 5, 3%)
- Family illness n=2
- Unwell n=2
- Unknown n=1
Pregnancy loss
Stillbirth (n=1, (0.5%))
In the study at 28 weeks gestation (n=167, 83%)
In the study at 36 weeks gestation (n=161, 80%)
Fig. 1 Participant flow through the study. Note: Women attending clinic for follow up did not necessarily provide useable home BP data
0%
25
%
50
%
75
%
%001
20 22 24 26 28 30 32 34 36 38 40
Gestation (weeks)
Mean gestation
Fig. 2 Persistence of self-monitoring. Of 162 who self-monitored, 160 started before 20 weeks gestation and, of these, 12 stopped at or before
20 weeks. The graph presents the remaining 148 patients (74% of the 201 total population, and 91% of the 162 who self-monitored). Mean gestation
at delivery is indicated by the dotted line (38.2 weeks)
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eclampsia. Of the further 13 (8%) women with chronic
hypertension, 5 (3%) developed pre-eclampsia and 3 (2%)
had worsening hypertension but not proteinuria.
Of the 28 (18%) women with a final diagnosis of
pregnancy-induced hypertension, 5 (18%) had stopped
self-monitoring by diagnosis. Using a common threshold
for raised BP of 140/90 mmHg for both clinic and home
BP, of the remaining 23 women, 9 (39%) had a raised home
BP prior to raised clinic BP, 5 (22%) had a raised home BP
on the same date or after the raised clinic reading, and 9
(39%) only had a raised clinic BP (Additional file 4:
Table S1). Considering the 129 (82%) of those with
diagnostic verdicts but no final diagnosis of gestational
hypertension and/or pre-eclampsia, 25 (19%) had at
least one episode of raised home BP and 33 (26%) had
at least one episode of raised clinic BP. Of the 152 who
did not have a raised clinic BP and/or a raised home BP
prior to 12 weeks, the times to detection of first raised
BP for clinic and home BPs were not significantly dif-
ferent (Fig. 4a, p=0.9).
In detecting hypertension, home monitoring achieved
a sensitivity of 61%, specificity of 81%, a positive predict-
ive value of 36% and a negative predictive value of 92%
(Additional file 4: Table S2). Additional appointments
due to raised home blood pressure were apparently in-
frequent but this should be treated cautiously as there
may have been under reporting.
In sensitivity analyses, two changes in the diag-
nostic criteria were assessed, including a) the first BP
measured at home (Fig. 4b) and b) reducing the self-
monitored threshold for raised BP to 135/85 mmHg
(retaining 140/90 mmHg for clinic) (Fig. 4c and
Additional file 4: Table S1). Both changes increased
sensitivity but reduced specificity: both increased the
number of women with hypertension initially detected
at home from 9 (39%) to 14 (61%) and made the time
to detection significantly shorter than detection based
on clinic BP readings (P < 0.01) (Additional file 1:
Tables 2 and 3). However, the inclusion of the first
BP measured at each session increased the number of
normotensive women with at least one episode of
raised home BP from 25 (19%) to 49 (38%). Changing
the threshold for raised BP at home to 135/85 mmHg,
increased the number of normotensive women with at
least one episode of raised home BP from 25 (19%)
to 45 (35%).
Fig. 3 Clinic and home blood pressure readings through pregnancy.
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Discussion
Main findings
This study has shown that a range of women with differ-
ent risk factors for hypertension in pregnancy were willing
to take part in a study of self-monitoring of BP. Recruit-
ment took place from a variety of settings, including both
primary and secondary care, with the largest numbers of
women recruited from hospital sites. Most participants
(85%) were successfully trained to self-monitor and, whilst
retention in the study was adequate (80%), persistence
with self-monitoring to 36 weeks was less so (66%).
In this observational study, clinic readings were used
to determine a final diagnosis of hypertension. As ex-
pected clinic BP monitoring alone had a sensitivity of
100%, with home monitoring achieving a sensitivity of
61%, specificity was higher with home monitoring (81%
vs 74% for clinic monitoring). Home monitoring had a
similar positive and negative predictive value to clinic
monitoring suggesting that home monitoring is an ap-
propriate intervention to trial formally.
Is this the correct population to consider for self-monitoring?
This study recruited women at higher risk of pre-eclampsia
of which, 18% developed pregnancy-induced hypertension
and 6% pre-eclampsia, around double that expected in the
overall pregnant population [28]. A population with more
than a 1:6 chance of developing a hypertensive disorder of
pregnancy would seem appropriate to formally test effect-
iveness and cost-effectiveness of a self-monitoring interven-
tion. Earlier diagnosis could have a significant impact on
pregnancy health care of women, improving the manage-
ment of hypertension and therefore potentially reducing
the number of adverse outcomes relating to gestational
hypertension and pre-eclampsia.
Which are the correct thresholds to use?
Self-monitored readings were similar in value to con-
temporaneous matched clinic readings for both systolic
and diastolic BP in terms of overlapping confidence in-
tervals with point estimates largely within 5 mmHg.
Outside of pregnancy, home readings are generally
a
b
c
Fig. 4 Time to the first raised blood pressure. a Time to first raised blood
pressure excluding the first home reading taken in any monitoring
session and using thresholds for hypertension of 140/90mmHg for home
and clinic. n=152*, 50 (33%) had a raised clinic BP reading, 43 (28%) has
a raised home BP reading. b Sensitivity analysis 1: Time to first raised
blood pressure including the first home reading taken in any monitoring
session and using thresholds for hypertension of 140/90mmHg for home
and clinic. n=151, 49 (32%) has a raised clinic BP reading, 69 (46%) has a
raised home BP reading. c Sensitivity analysis 2: Time to first raised blood
pressure excluding the first reading taken in any monitoring session and
using thresholds for hypertension of 135/85mmHg for home and 140/
90mmHg for clinic. n=152*, 50 (33%) has a raised clinic BP reading, 69
(45%) had a raised home BP reading
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considered to be lower than clinic pressures however
this is largely due to selection for a white coat effect in-
herent in a diagnosis of hypertension on the basis of
clinic readings [29]. This study used identical thresholds
for action for home and clinic readings, resulting in 39%
(albeit of only 23 individuals) detecting definitively
raised BP at home prior to the clinic. The sensitivity
analysis suggested that earlier diagnosis of hypertension
was possible in over 60% with the use of lower home
thresholds. This was at the expense of a significant num-
ber of false positives. Considering pharmacological inter-
vention does not currently happen until a threshold of 150/
100 mmHg in the clinic [28] a regime of increased moni-
toring at a threshold of 135/85 mmHg at home, with refer-
ral to clinic for those with persistently raised home BP of
140/90 mmHg may be an appropriate compromise. Under-
standing whether this is an appropriate intervention to jus-
tify home monitoring on a wide scale to detect pregnancy
induced hypertension requires a properly powered trial.
Strengths and limitations
Considering the availability and uptake of self-monitoring
equipment in adults with hypertension, there are remark-
ably few data concerning its use in pregnancy [30, 31].
This study recruited over 200 participants from diverse
settings including inner-city and more rural sites, both
teaching and district general hospitals, several GP prac-
tices and 20% from minority ethnic groups. The monitor
provided to participants was one of the few validated for
use in both pregnancy and pre-eclampsia hence the results
from self-monitoring should be robust [20]. Almost 20%
of women provided no or insufficient self-monitored read-
ings and this may reflect a need for better training in order
to maximise retention. 25% of those who were successfully
trained to self-monitor did not persist with it, anecdotally
for a range of reasons including lack of time, family illness
or moving away. Education, training and methods of im-
proving motivation for self-monitoring throughout preg-
nancy should be considered in future work.
Clinic BP was not systematically measured with identi-
cal equipment in each case and so the comparisons with
home BP may be flawed. Such between centre differences
are inevitable in a pragmatic observational study such as
this and reflect the need for stratification by centre in
future randomised work.
In this study self-monitoring did not always detect
raised readings before clinic readings; this may represent
white coat hypertension in these instances and warrants
further study [32].
Comparison with other literature
Self-monitoring of BP will increase women’s involvement
with their antenatal care. Previous work has shown that
pregnant women are happy to undertake the additional
monitoring [33] and find home monitoring more accept-
able than more frequent clinic visits [34] or ambulatory
monitoring [32, 35]. This was confirmed in our linked
qualitative work which will be reported separately [36].
The only randomised trial of self-monitoring of BP in
pregnancy to date showed that even a weekly schedule
of self-monitoring increased the likelihood of BP moni-
toring in any given week and therefore increased the
likelihood of detection of raised BP [37].
Previous studies that have assessed both clinic and
home BP during pregnancy present conflicting results
regarding differences in absolute levels, with some finding
that home readings were lower on average than clinic
readings while others reported the reverse [15, 16, 38–41].
None of these studies used a validated monitor, making
comparisons difficult. The largest of these studies found a
stable home-clinic difference throughout, similar to that
seen here (within 5 mmHg) [40]. Further data regarding
relative thresholds for self-monitoring are currently being
analysed in an individual patient data meta-analysis [22].
Other work to improve the prediction or early detection
of gestational hypertension and pre-eclampsia has focused
on risk factors and circulating biomarkers. Biomarkers
with promise include factors involved in endothelial and
immune response, cardiovascular markers and metabolic
factors [42, 43]. The large range of biomarkers under in-
vestigation reflects the fact that pre-eclampsia is a multi-
factorial and multisystem disease [44]. Detection of raised
BP by self-monitoring could be complementary to these
emerging screening strategies.
Conclusion
Taken together, these results suggest that women at risk
of hypertension in pregnancy are able to self-monitor BP
and that this strategy has the potential to detect gesta-
tional hypertension prior to clinic readings. However a
larger trial, which will require superior training and re-
tention approaches, is required to understand the true
effectiveness and cost-effectiveness of self-monitoring of
BP in the detection of hypertension in pregnancy.
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